Molecular changes induced by the curcumin analogue D6 in human melanoma cells
© Rozzo et al.; licensee BioMed Central Ltd. 2013
Received: 30 November 2012
Accepted: 26 April 2013
Published: 4 May 2013
In a previous report, we described the in vitro and in vivo antiproliferative and proapoptotic activity of a hydroxylated biphenyl (D6), a structural analogue of curcumin, on malignant melanoma and neuroblastoma tumours. In this paper, we investigated the molecular changes induced by such a compound, underlying cell growth arrest and apoptosis in melanoma cells.
To shed light on the mechanisms of action of D6, we firstly demonstrated its quick cellular uptake and subsequent block of cell cycle in G2/M phase transition. A gene expression profile analysis of D6-treated melanoma cells and fibroblasts was then carried out on high density microarrays, to assess gene expression changes induced by this compound. The expression profile study evidenced both an induction of stress response pathways and a modulation of cell growth regulation mechanisms. In particular, our data suggest that the antiproliferative and proapoptotic activities of D6 in melanoma could be partially driven by up-regulation of the p53 signalling pathways as well as by down-regulation of the PI3K/Akt and NF-kB pathways. Modulation of gene expression due to D6 treatment was verified by western blot analysis for single proteins of interest, confirming the results from the gene expression profile analysis.
Our findings contribute to the understanding of the mechanisms of action of D6, through a comprehensive description of the molecular changes induced by this compound at the gene expression level, in agreement with the previously reported anti-tumour effects on melanoma cells.
Melanoma is the most aggressive form of skin cancer. Its incidence and mortality have risen dramatically in all developed countries during the last half century . Although most cases of melanoma are diagnosed early and surgically resected, later stages of this tumour have very poor survival rates because of the lack of available effective therapies [1–3]. Recently, promising therapeutic approaches for melanoma management have been introduced into the clinical practice, based mostly on the use of small-molecule inhibitors directed against oncogenic molecular targets as well as on immunotherapy [4–7]. However, a high molecular heterogeneity of melanoma tumours and a complex network of proliferation and survival pathways involved in its pathogenesis have been reported [8, 9]. For this reason, there is a growing interest in seeking pharmacological agents that could target multiple gene products in order to interfere, at different levels, with pathogenetic pathways in melanoma. During the last decades, several dietary agents have been reported to exert anticancer activity. They commonly show multifaceted effects on cancer cells by inducing molecular changes related to different mechanisms of carcinogenesis: proliferation, apoptosis, invasion, and metastasis . An innovative therapeutic approach to manage melanoma may be represented by the introduction into clinical trials of naturally occurring compounds (such as eugenol, resveratrol, green tea, curcumin and other), whose antiproliferative and/or proapoptotic activity against malignant melanoma - in both in vitro and in vivo models - has been already demonstrated . Among them, curcumin, a polyphenol extracted from the rhizome of the plant Curcuma longa, has been frequently reported to exert promising anticancer activity on several tumours . This molecule is highly pleiotropic, is able to enter cells , and interacts with numerous targets . Strong evidence demonstrated that curcumin inhibits proliferation, invasion, angiogenesis, and metastasis in several types of cancer through interaction with multiple cell signalling proteins (reviewed in [15, 16]). Recently, curcumin has been shown to exert a good antiproliferative activity by inducing apoptosis in malignant melanoma . One of the most important pathway involved in the curcumin antitumour activity is the nuclear factor-kB (NF-kB) pathway , particularly in melanoma cells. Indeed, curcumin is able to suppress the activation and phosphorylation of the inhibitor of NF-kB alpha (IkBa) by inhibiting the IkB kinase (IKK) and NF-kB activity in human melanoma cell lines [19, 20]. Moreover, curcumin induces cell apoptosis and cell cycle arrest in G2/M phase in melanoma, through up-regulation of p53, p21, p27 and checkpoint kinase 2 .
Recently, our group has synthesized a new curcumin-related biphenyl structure (an αβ unsaturated ketone called D6) whose antiproliferative and proapoptotic activities on melanoma cell lines were more effective, rapid and selective than those induced by curcumin. The D6 compound was proved to promote apoptosis in melanoma cells through the mitochondrial intrinsic pathway . In vivo assays on mouse models confirmed the potential of D6 against melanoma, showing a significant reduction of the tumour mass growth as compared to untreated control .
To investigate the mechanisms of action of the D6-curcumin analogue against melanoma at the molecular level, we here studied its cellular uptake and its influence on cell cycle progression. Finally, a gene expression profile analysis of D6-treated melanoma cell lines was carried out on high density microarrays, in order to explore the molecular pathways activated after D6 enters cells. This genomic technology is useful to dissect the molecular changes occurring inside cancer cells, and it is well documented for malignant melanoma [22, 23]. In our study, the LB24Dagi (LB24) primary melanoma cell line was selected for all the analyses, because it had been previously demonstrated to be the most sensitive line to D6 treatment among tested ones . Several molecular changes that can justify the antiproliferative and proapoptotic properties of D6 on melanoma cells and likely contribute to its anti-tumour effect have been here presented and discussed.
D6 enters melanoma cells
D6 blocks cell cycle at G2/M transition
D6 treatment induces transcriptional changes in melanoma cells and normal fibroblasts
To analyze gene expression modifications induced by D6 treatment on melanoma cells, we carried out gene expression profile analyses on LB24 primary melanoma cell line, either treated or not (negative control) with 10 μM D6, using high density microarrays (see Methods). Same analysis was performed on human fibroblasts cells (BJ cell line) as normal control, which have been previously demonstrated to be insensitive to D6 .
Transcriptional changes induced by D6 treatment in melanoma cells and normal fibroblasts
Differentially expressed transcripts
(0.5 > FC > 2)
(FC > 2)
(FC < 0.5)
LB 24 DAGI Melanoma cells
The two lists of selected probes were analysed by the Ingenuity Pathway Analysis (IPA) software. Results obtained on melanoma cells are reported in Additional file 1-B and 1-C. IPA results obtained for BJ fibroblasts are reported in Additional file 2-B and 2-C.
D6 treatment affects cell death and proliferation bio-functions
Melanoma top bio functions
N. of molecules
1 Cell death
3.34E-15 – 3.24E-02
2 Cellular function and maintenance
6.17E-14 – 3.24E-02
1.22E-13 – 3.24E-02
4 Cell cycle
9.64E-12 – 3.15E-02
5 Cellular growth and proliferation
1.16E-11 – 3.15E-02
The lowest p-values were found for the Cell Death category with 194 molecules involved (Table 2, n. 1). Cell death is indeed the primary effect detected on melanoma cells after D6 treatment . Moreover, a variable number of molecules differentially modulated by D6 involved functional categories strictly correlated with cell proliferation processes such as cellular function and maintenance, cell cycle and cell growth and proliferation (Table 2, n. 2–5).
D6 induces stress response pathways and down-regulates cell proliferation pathways
Melanoma top canonical pathways
Ingenuity canonical pathways
1 Aldosterone Signaling in Epithelial Cells
2 Protein Ubiquitination Pathway
CRYAB,UBE2H,HSPA7,DNAJB4,HSPA1A/HSPA1B,HSPA6,DNAJC3,DNAJB2, HSPA5,DNAJA1,HSPA4,HSPA1L,STUB1,HLA-B, DNAJB1, BRCA1, HSPA4L, MED20, HSPH1, PSMC4, USP30, HSPD1, DNAJB9, DNAJB14, SKP2 (includes EG:27401), ANAPC4, PSMD12, HSPA13, DNAJB6, UBC, UBE2D3
3 NRF2-mediated Oxidative Stress Response
NRAS,DNAJB4,HERPUD1,DNAJC3,DNAJB2,DNAJA1,DNAJB9,DNAJB14,MAFF, TXNRD1, FOS, HMOX1, JUN, ATF4, MAP2K3, FOSL1, PIK3R2, SQSTM1, DNAJB6, DNAJB1, GCLM, EIF2AK3
4 Cell Cycle: G2/M DNA Damage Checkpoint Regulation
CDC25B, GADD45A, CDKN1A, TOP2A, CCNB2, PKMYT1, BRCA1, SKP2 (includes EG:27401), CCNB1
5 p53 Signaling
PMAIP1, GADD45B, THBS1, TNFRSF10B, TP53BP2, SERPINE2, SCO2 (includes EG:606683), JUN, GADD45A, CDK4, ADCK3, CDKN1A, PIK3R2, BRCA1
6 VDR/RXR Activation
GTF2B,LRP5, GADD45A, MXD1, HOXA10, CDKN1A, IGFBP3, CD14, CST6 (includes EG:1474), CSF2, RXRA, KLF4
7 Pyrimidine Metabolism
POLE2, DCTPP1, UPP1, POLQ, DKC1, DTYMK, RFC5, POLRMT, PUS1, TXNRD1, POLR1C, POLD3, PNP, POLA2, UNG, ENTPD7
8 Mitotic Roles of Polo-Like Kinase
CDC25B, PPP2CB, ANAPC4, PLK2, CDC7 (includes EG:12545), CCNB2, PKMYT1, ANAPC13, CCNB1
9 IGF-1 Signaling
SOCS1, CSNK2A2, FOS, JUN, NRAS, CTGF, NOV, IGFBP3, PRKAG2, IRS2, PIK3R2, CYR61
10 Hereditary Breast Cancer Signaling
NRAS, GADD45B, FANCG, RFC5, CCNB1, PALB2, GADD45A, CDK4, XPC, CDKN1A, PIK3R2, UBC, BRCA1
11 ATM Signaling
JUN, GADD45B, GADD45A, CDKN1A, CCNB2, ATF4, BRCA1, CCNB1
12 RAR Activation
RDH14, BMP2 ,CSK, ADCY3, SMAD5, NFKB1, VEGFA, FOS, CSNK2A2, JUN, TAF4 (includes G:100149942), DUSP1, CRABP2, IGFBP3, PRKAG2, PIK3R2, RXRA
13 Cyclins and Cell Cycle Regulation
PPP2CB, E2F6, TFDP1, CDK4, SUV39H1, CDKN1A, E2F5, CCNB2, SKP2 (includes EG:27401), CCNB1
14 p38 MAPK Signaling
FADD, DDIT3, DUSP1, DUSP10, MEF2D, H3F3A/H3F3B, ATF4, MAP2K3, MKNK2, EEF2K, H3F3C, IRAK2
15 Pancreatic Adenocarcinoma Signaling
VEGFA, HMOX1, E2F6, TFDP1, CDK4, SUV39H1, CDKN1A, E2F5, HBEGF, PIK3R2, ERBB2, NFKB1
16 Renal Cell Carcinoma Signaling
17 Cell Cycle Regulation by BTG Family Proteins
18 Retinoic acid Mediated Apoptosis Signaling
FADD,TNKS,CRABP2,TNFRSF10B,TNFRSF10D,RXRA,TIPARP,IRF1 (includes EG:16362)
19 Glucocorticoid Receptor Signaling
IL8,NRAS,HSPA7,SGK1,HSPA1A/HSPA1B,HSPA6,NFKB1,HSPA5,TAF13 (includes EG:310784),FOS,HSPA4,GTF2B,TAF6L,JUN,TAF4 (includes EG:100149942),HSPA1L,DUSP1,CDKN1A,FKBP4,PRKAG2,PIK3R2,CSF2
20 Toll-like Receptor Signaling
FOS,LY96 (includes EG:17087),JUN,CD14,MAP2K3,NFKB1,IRAK2
21 Endoplasmic Reticulum Stress Pathway
22 Neurotrophin/TRK Signaling
23 Molecular Mechanisms of Cancer
24 Chronic Myeloid Leukemia Signaling
25 Cell Cycle: G1/S Checkpoint Regulation
E2F6,TFDP1,CDK4,SUV39H1,CDKN1A,E2F5,SKP2 (includes EG:27401)
26 Role of BRCA1 in DNA Damage Response
27 Role of CHK Proteins in Cell Cycle Checkpoint Control
28 Bladder Cancer Signaling
29 IL-17A Signaling in Gastric Cells
30 Role of Tissue Factor in Cancer
31 HMGB1 Signaling
32 ERK/MAPK Signaling
33 Non-Small Cell Lung Cancer Signaling
34 Prostate Cancer Signaling
35 RAN Signaling
36 Cell Cycle Control of Chromosomal Replication
MCM3,CDK4,ORC5 (includes EG:26429),CDC7 (includes EG:12545)
37 IL-6 Signaling
38 IL-2 Signaling
39 MIF Regulation of Innate Immunity
FOS,LY96 (includes EG:17087),JUN,CD14,NFKB1
40 Role of IL-17F in Allergic Inflammatory Airway Diseases
41 Erythropoietin Signaling
42 Estrogen Receptor Signaling
TAF6L,GTF2B,NRAS,TAF4 (includes EG:100149942), MED20, H3F3A/H3F3B, MED16,HNRNPD,TAF13 (includes EG:310784),MED10,H3F3C
Melanoma modulated genes
Additional pathways such as 4 -Cell cycle: G2/M DNA damage checkpoint regulation, 5 -p53 signalling, 10 -Hereditary breast cancer signalling, 11 -ATM signalling, 26 -Role of BRCA1 in DNA damage response, and 27 -Role of CHK proteins in cell cycle checkpoint control are all related to DNA repair mechanisms and cell death triggering (Table 3 and Additional files 3, 4, 5, 6, 7, 8), evidencing a DNA damage as cell response to D6 treatment.
The up-regulation of pathway 5- p53 signalling (Figure 3, Additional file 4), which acts in response to cell injury or DNA damage by controlling cell proliferation and driving cells to apoptosis, is noteworthy and points out a central role of this regulatory protein in the D6 anticancer effect on melanoma cells. Indeed, induction of p53 activity was evidenced by up-regulation of some p53 target genes: CDKN1A (FC = 19.35), GADD45A and B (FC = 7.78 and FC = 7.47, respectively), all codifying for inhibitors of the cell cycle, and PMAIP1 (FC = 6.08) codifying for Noxa, a pro-apoptotic BH3 only protein of the Bcl2 family (Table 4). A slight up-regulation of TP53BP2 gene (FC = 2.36), codifying for ASSP2 - a member of the ASPP (apoptosis-stimulating protein of p53) family of p53 interacting proteins, confirms the role of p53 as an apoptosis activator in our system.
Down-regulation of pathways controlling cell proliferation such as pathways 4-Cell cycle:G2/M DNA damage checkpoint regulation, 8 -Mitotic roles of PLK, 13 -Cyclins and cell cycle regulation, 23 -Molecular mechanisms of cancer and 25 -Cell cycle: G1/S checkpoint regulation was also observed (Figure 3, green bars). These alterations seem to be related to the down-regulation of important cell-cycle “motors” like CCNB1/2 (cyclin B1 and 2), CDC25, and CDK4 (Tables 3 and 4, Additional files 3, 9, 10, 11, 12).
Other interesting features highlighted by the pathway analysis are the partial down regulation of phosphatidylinositol 3 kinase - regulatory subunit 2 (PIK3R2, FC = 0.48) and nuclear factor-kB1 (NFKB1, FC = 0.47) genes (Table 4). On this regard, both PIK3R2 and NFKB1 are greatly represented in the melanoma most significant pathways listed in Table 3 (19 and 13 out of 42 pathways, respectively).
D6 modulates the expression of several life and death regulator genes
Beside the modulated genes highlighted by the pathway analysis, FC analysis evidenced some other genes whose modulation might have a role in the observed antiproliferative and pro-apoptotic activities of D6 on melanoma cells (Additional file 1-A) . Among them, the CCNF gene that codifies for the G2/mitotic-specific cyclin-F was highly down-modulated (FC = 0.24, Table 4). Cyclin F is produced in the G2 cell cycle phase and is essential for fidelity of mitosis; therefore, a down-modulation of such protein may interfere with the progression of cell division, which is consistent with the block of cell cycle in G2/M phase observed upon D6 treatment (Figure 2).
Among the down-regulated genes (FC < 0.5), we found an evident under-expression of the c-KIT proto-oncogene (FC = 0.30), whose activation is often associated with increased cell proliferation, specifically in melanoma (Table 4) . Down regulation of c-KIT is then likely to be related to D6 anticancer activity on melanoma cells, contributing to inhibit cell-proliferation signals.
We already demonstrated that D6 treatment induces apoptosis in melanoma cells through the mitochondrial intrinsic pathway . Looking at gene expression levels of the apoptosis-related genes, we observed a strong up-regulation of DDIT3 (DNA–damage-inducible transcript 3, FC = 11.1), a transcription factor activated in endoplasmic reticulum stress conditions that promotes apoptosis by induction of caspases , as well as a discrete over-expression of the gene BCL10 (FC = 3.93), encoding for a pro-apoptotic member of the Bcl2 family proteins , in addition to the over-expression of the protein Noxa codified by PMAIP1 mentioned above (FC = 6.08) (Table 4). These are further evidences about the involvement of pro-apoptotic signals in D6 treated cells.
Expression profile changes in D6 treated fibroblasts
The IPA-based analysis of the 1,883 transcripts modulated by D6 in fibroblasts (listed in Additional file 2-A) was useful to compare results with those obtained in melanoma cells. Biological function categories found to be significant in fibroblasts were similar to those selected for melanoma cells (Additional file 2-B), suggesting that D6 treatments involve life and death controlling mechanisms also in normal cells. However, D6 treated fibroblasts did not show significant effects in terms of block of proliferation or induction of apoptosis, as we previously described . The analysis of D6 treated fibroblasts evidenced the involvement of the pathways underlying general cell stress responses (Additional file 2-C). However, processes including chaperones activation and protein degradation were less significant in fibroblasts than in melanoma cells (Additional file 2-C, pathways 10, 16, 21), with some HSPs being down-modulated. Conversely, DNA damage induced cell response pathways were highly significant in fibroblasts also (see Additional file 2-C, pathways 2, 3, 4, 5, 9, 18), indicating that D6 even triggers an anti-mitotic reaction in normal cells (though not confirmed in the biological assays ). Such a response was anyway weaker in these latter cells and pathway trends markedly differed between melanoma and fibroblasts (i.e., p21/CDKN1A, FC = 19.35 in melanoma cells versus FC = 4.29 in fibroblasts, or CCNB1, FC = 0.43 and CDC25B, FC = 0.47 in melanoma cells with no modulation in fibroblasts; Table 4). Furthermore, neither PIK3R2 nor NFKB1 gene expressions were altered in fibroblasts, suggesting that the relative pathways are not hindered by D6 in these normal cells. These data suggest that D6 interaction with both PI3K/Akt and NF-kB signal transduction cascades may be peculiar of its activity on cancer cells.
Protein levels reflect gene expression changes in D6 treated melanoma cells
Figure 4A shows the increased protein levels detected by western blot for the three major p53 targets modulated by D6: p21, GADD45A, and Noxa. The p21 protein was about 2.5 fold more expressed in treated cells compared to the untreated ones, confirming the increase of CDKN1A gene expression. Same increased levels were observed for the GADD45-A protein, while Noxa protein levels were about 70% higher as compared to those of control cells.
Among the proteins involved in regulation of cell cycle G2/M phase transition, we performed immunoblot assays for cyclin B, cdc25, and cyclin F. Protein levels detected in D6 treated cells were much lower than those of untreated ones, thus confirming the decrease of expression observed in microarrays analysis (Figure 4B).
An almost complete depletion of the PI3K protein in treated cells compared to untreated ones is shown in Figure 4C, reflecting the under-expression of the PIK3R2 gene and suggesting a possible down-regulation of PI3K/Akt pathway. To confirm such an inhibitory effect, we investigated the Akt activation status and performed an immunoblot analysis using a specific anti phospho-Akt antibody. Expression of AKT gene itself was not modulated after D6 treatment (data not shown), but its phosphorylation/activation status was decreased of about 75% (Figure 4C). Down-modulation of c-KIT gene expression was also confirmed by western blot analysis, which showed that c-kit protein level was decreased of about 65% (Figure 4C).
Finally, an up-modulation of the DDIT3 and Bcl10 protein expression levels upon D6 treatment was confirmed by western blot analysis (Figure 4D).
In this paper, we demonstrate that the curcumin analogue D6 is able to enter melanoma cells reaching a peak in about two hours (see Figure 1), and give rise to a series of molecular changes that underlie the previously described anti-tumour activity of such a compound .
Our results indicated that D6 treatment may promote a block of cell cycle progression in G2 phase (see Figure 2) and this could represent one of the mechanisms that inhibit melanoma cells growth, as previously observed . Alterations in cell cycle progression are indeed important events in cancer development and hindering such altered mechanism has been often used as a good strategy to inhibit tumour growth .
To investigate the possible molecular mechanisms triggered by D6 treatments, we undertook a gene expression profile analysis on melanoma cancer cells and fibroblast normal cells. Our primary objective was to identify genes that were up- or down-regulated in response to treatment, and which could be related to the phenotypic outcome. Two lists of regulated transcripts (0.5 > FC > 2), one for LB24 melanoma cells and the other for BJ fibroblasts were selected (Additional file 1-A and 2-A, respectively) and subsequently analyzed by the IPA software. Considering both the most significant functional categories and canonical pathways (see Tables 2 and 3, respectively), the activity of D6 compound in melanoma cells is certainly based on either cell stress responses either activation/repression of mechanisms regulating cell survival. Pathway analysis revealed up-regulated effectors of cell stress response and protein degradation as well as down-regulated gene products controlling cell proliferation (see Figure 3). The activation of cell defence pathways observed on melanoma cells (Table 3, pathways 1–3) indicates that D6 treatment causes important stimulation of the cellular stress response, with a strong induction of HSPs, which in turn affects cell survival and drives toward cell death [28–30]. In physiological or pathological conditions, cellular stress leads to transport and accumulation of damaged proteins in the endoplasmic reticulum where they should be repaired or committed to degradation. This stimulates the over-expression of chaperons and HSPs that perform a sort of quality control and drive seriously damaged proteins to ubiquitination and proteasome degradation. When endoplasmic reticulum functions are strongly compromised, this organelle triggers apoptotic signals in order to eliminate the irreversibly damaged cell . In our model, several HSPs genes show to be up-regulated (see Table 3), and HSPA6 is the most over-expressed transcript (FC = 368.61, Table 4). It codifies for the stress inducible Hsp70B’ protein, normally under-expressed or absent in most cell types, whose expression is strictly linked to that of Hsp72 (gene HSPA1A, FC = 20.35, Table 4); both these proteins have a key role in mediating cell survival during endoplasmic reticulum proteotoxic stress conditions . One could speculate that their huge increase of expression levels following D6 treatment could be related to the extreme endoplasmic reticulum stress response that finally directs melanoma cells to death by triggering apoptosis. In support of this hypothesis, our analysis evidenced a strong induction of the DDIT3 gene (FC = 11.1, Table 4), also known as growth arrest and DNA damage-inducible gene 153 (GADD153), which is one component of the ER stress-mediated apoptosis pathway . Increased expression of GADD153 by curcumin has been previously reported as one of the first steps toward apoptosis in colon cancer cells , thus confirming a possible contribution in this sense in D6 treated melanoma cells also.
Analogously, D6 stimulated cell stress response pathways in fibroblasts, but at a lower level compared to melanoma cells (Additional file 2-C). This is confirmed by the over-expression of single genes - like several HSPs and DDIT3 (Table 4), which is presumably milder or not sufficient to promote cell death .
One noteworthy feature occurring in melanoma cells upon D6 treatment - as evidenced by IPA - is an up-regulation of the p53 signalling pathway (Figure 3). The p53 tumour suppressor protein is a key transcriptional regulator that responds to a variety of cellular stresses and controls key cellular processes such as DNA repair, cell-cycle progression, angiogenesis, and apoptosis. The p53 protein thus acts like a “driver”, which can either save injured cell by inducing damaged DNA repair and let it to re-enter cycle or sacrifice it by stimulating both cell cycle arrest and apoptosis [34, 35]. In our model, up-regulation of p53 signalling pathways seems to have a key role in mediating both antiproliferative and pro-apoptotic effects of D6 on LB24 melanoma cells (see Additional file 4). Indeed, a strong up-regulation of some p53 target genes has been detected and could explain the anticancer effects of D6: CDKN1A and GADD45A/B - that are strong inhibitors of cell cycle G2/M transitions [36, 37], might be responsible for the block of cell cycle at G2 phase, and Noxa - a pro-apoptotic BH3-only protein of the Bcl-2 family, may account for the apoptotic cell death . As a confirmation of this, the expression of CDKN1A gene codifying for the CDK inhibitor p21 is about 20 times higher in treated melanoma cells (FC = 19.35, Table 4). The p21 protein belongs to the Cip/Kip family of inhibitors and inactivates CDK-cyclin complexes [36, 39]. In our system, it seems to regulate large part of melanoma cells response to D6 compound, being a component of most pathways identified by IPA (Table 3, pathways 4, 5, 6, 10, 11, 13, 15, 19, and 23; see also Additional files 3, 4, 5, 6, 7, 8, 10, 11, 12). The strong up-regulation of GADD45A and B (respectively FC = 7.78 and FC = 7.47; see Table 4) also appears to influence several growth controlling pathways (Table 3, pathways 4, 5, 6, 10, 11, and 26; see Additional files 3, 4, 5, 6, 7). Proteins encoded by these two stress induced genes are involved in regulation of growth and apoptosis and may cooperate in inhibiting cell growth [37, 40]. Over-expression of the BH3-only Noxa protein codified by the PMAIP1 gene (FC = 6.08, Table 4) suggests that D6 induced apoptosis could be partially p53 dependent. Noxa and Puma (p53-upregulated modulator of apoptosis) proteins are in fact direct targets in p53-mediated apoptosis at mitochondrial level [38, 41], functioning as “sensors” for apoptotic signals. Thus, increased Noxa levels could participate in initiating the apoptotic cascade in D6 treated melanoma cells. Supporting this hypothesis, a slight up-regulation of the TP53BP2 gene has been reported in our melanoma model (FC = 2.36, Table 4). This gene encodes for ASPP2, a member of the ASPP (apoptosis-stimulating protein of p53) family of p53 interacting proteins, which regulate the apoptotic function of p53 and its family members, p63 and p73. Biochemical and genetic evidences have shown that ASPP1 and ASPP2 activate the apoptotic but not the cell-cycle arrest function of p53 . The increased levels of ASPP2 protein observed in D6 treated melanoma cells might thus induce p53 to trans-activate its pro-apoptotic target genes, resulting in the observed over-expression of Noxa, and subsequent activation of mitochondrial intrinsic apoptosis. Another evidence of pro-apoptotic signals in D6 treated cells expression profile is the over-expression of the BCL10 gene (FC = 3.93, Table 4), encoding for a pro-apoptotic member of the Bcl2 family proteins. Bcl10 protein contains a caspase recruitment domain (CARD) motif and promotes the activation of caspase-9 .
The p53 signalling pathway has resulted to be significantly affected also in fibroblasts (Additional file 2-C), being CDKN1A and GADD45 A/B partially up-regulated. Again, this molecular response in fibroblasts is weaker than that in melanoma cells (CDKN1A FC = 4.29, Table 4), without causing in normal cells block of proliferation or cell death.
Our analyses pointed out a down modulation of cell cycle regulators cyclin B1, cdc25B, and CDK4 (Table 4), which certainly contributes to the inhibition of cell proliferation exerted by D6 on melanoma cells. Block of cell cycle in G2/M phase perfectly matches with a decrease in expression of both cyclin B (the mitotic switching cyclin) and cdc25 (the CDK1 activating phosphatase), whereas the decrease in CDK4 expression indicates that cells lack entering the cell cycle while are driven to age and die , as demonstrated by the G1 cell population decrease after D6 treatment (see Figure 2). Interestingly, a lower or absent down-modulation of these mitosis promoters has been evidenced in fibroblasts (Table 4), suggesting that D6 treatment specifically inhibits cell proliferation pathways in melanoma cells.
Another gene down-modulated by D6 in melanoma cells (and not in fibroblasts) is the CCNF gene (FC = 0.24, Table 4), codifying for cyclin F, the founding member of the F-box protein family . In addition to an F-box domain, cyclin F contains a cyclin-box domain, but, in contrast to typical cyclins, it does not bind or activate any cyclin-dependent kinases (CDKs). However, like other cyclins, cyclin F protein levels vary during the cell division cycle, peaking in G2. During G2, cyclin F is involved in ubiquitination and degradation of proteins  as well as in spindle formation and it is required for the fidelity of mitosis and genome . In our system, down-modulation of such a protein is in agreement with the block of cell cycle in G2/M phase demonstrated by cytofluorimetry (Figure 2).
A further contribution to D6 anticancer activity on melanoma cells is given by the down-modulation of the c-KIT proto-oncogene (FC = 0.30, Table 4). The c-kit protein belongs to class III receptor tyrosine kinases; its extracellular domain binds the SCF (stem cells factor) to stimulate several processes, including melanogenesis, gametogenesis, and haematopoiesis . The c-KIT up-regulation is often associated with increased cell proliferation; its down-regulation in D6 treated melanoma cells was confirmed by western blot analysis (Figure 4C).
One could also hypothesize that a big contribution to the anticancer activity of D6 is given by down-regulation of both phosphatidylinositol 3-kinase (PI3K) and NF-kB signalling pathways. There is growing evidence that activation of the PI3K/Akt pathway plays a significant role in melanoma (reviewed in ). Our results are consistent with an inhibition of PI3K/Akt pathway activation in melanoma cells following D6 treatment. As also confirmed by western blot analysis, a decreased expression of the PIK3R2 gene (FC = 0.48, Table 4), an almost complete depletion of the PI3K protein, and a 75% decrease of activated phospho-Akt have been observed in D6 treated cells (Figure 4C). In addition, a slight up-modulation of PTEN (Akt antagonist) gene expression was detected in our study (FC = 1.45, data not shown). The IκB kinase (IKK)/NF-κB signalling pathway is also often altered in tumours and NF-κB can affect all six hallmarks of cancer through the transcriptional activation of genes associated with cell proliferation, angiogenesis, metastasis, tumour promotion, inflammation and suppression of apoptosis (reviewed in ). PI3K and NF-kB signalling pathways are functionally linked, being NF-kB possibly activated by Akt kinase . Our results show that, similarly to PIK3R2, NFKB1 gene expression is down-regulated by D6 in melanoma cells (FC = 0.47), but it is unclear whether this could be due to the PI3K/Akt signalling repression. Deeper investigations should be made to shed light on this molecular event. However, it is interesting to underline that PI3K and NF-kB pathways are both involved in curcumin anti-tumour activity  and inhibition of NF-kB activation may account for curcumin efficacy on cancer cells  and, specifically, on human melanoma cells [19, 20]. As a consequence, it is likely that the curcumin analogue D6 shares some mechanisms of action with its natural compound, being even more effective in inhibiting tumour cells growth . It is noteworthy that neither PIK3R2 nor NFKB1 genes expression was modulated in D6 treated normal fibroblasts (Table 4). Based on these considerations, we can postulate that PI3K and NF-kB signalling down-regulation is strongly related to the anticancer activity of D6 on melanoma cells.
A further consideration may be done about a possible relationship between NFKB1 under-expression and p53 signalling up-regulation. An intense crosstalk exists among these two transcription factors that activate the expression of genes with opposite functions. They are indeed competitors for the transcriptional coactivator p300/CBP  and, depending upon which of them (NF-κB or p53) recruits this protein, different downstream pathways will be activated, resulting in either cell proliferation or growth arrest and apoptosis . To this regard, a recent report by Sen and colleagues  demonstrated that curcumin reverses doxorubicin resistance in breast cancer by inhibiting NF-κB activation and thus rescuing p300 coactivator, which in turn becomes available to the p53 transcription factor, and finally allows p53-dependent transactivation of proapoptotic proteins such as Bax, PUMA and Noxa. Based on these observations down-regulation of NF-κB by D6 would make the coactivator p300 available for recruitment by p53, thus favouring transactivation of its target genes that triggers antiproliferative and proapoptotic activity. This could be a very interesting feature of D6 because its potentiality to both inhibit NF-κB and, at the same time, rescue p53 signalling could be exploited either for direct therapeutic interventions against cancer, but also in combined therapies in order to sensitize resistant cancer cells to chemotherapeutic agents that can stimulate apoptosis by inducing DNA damages and triggering p53 apoptotic signals.
Altogether, our findings contribute to unveil the molecular mechanisms underlying the anti-tumour activity of D6 in melanoma cells. Based on such results, we can speculate that: a) p53 protein may play a key role in sustaining the anticancer effects exerted by D6 on melanoma cells; b) induction of strong cell stress responses may contribute to the reinforcement of the proapoptotic trend of p53 signalling; and c) down-modulation of several growth signals (c-kit, PI3K/Akt and NF-kB), as well as the under-expression of cell cycle regulators (cyclin B, cdc25 and CDK4) might be involved in cell growth inhibition. This last aspect seems to be peculiar of the response to D6 treatment in melanoma cells, being absent in D6-treated fibroblasts expression profile.
Although our analyses were not exhaustive, data here presented strongly indicate that a huge amount of molecular changes does participate in determining the molecular mechanism of action of D6 on melanoma cells. Gene expression profile analyses on additional melanoma cell lines are currently in progress, in order to either confirm our findings in a larger samples’ collection or evaluate the effects of D6 on both primary and metastatic tumour derived cell lines.
Cell cultures and D6 treatments
Malignant melanoma LB24Dagi (LB24) cell line was obtained from the Department of Molecular and Cellular Biology at the Istituto Dermopatico dell'Immacolata (IDI) in Rome (Italy). Normal human fibroblast BJ (CRL-2522) were purchased from the American Type Culture Collection (ATCC). All cells were grown in RPMI (Invitrogen, Carlsbad, CA, USA) media, supplemented with 10% FBS and penicillin-streptomycin (100 IU/50 μg/ml), as described . The αβ-unsaturated ketone D6 [(3E,3'E)-4,4'-(5,5',6,6'-tetramethoxy-[1,1'-biphenyl]-3,3'-diyl)bis(but-3-en-2-one)] (Figure 1A) has been synthesized in our lab as previously described . Stock solution of D6 was prepared by dissolving D6 in DMSO to a final concentration of 100 mM and stored at −20°C. Working solutions of D6 were prepared daily as previously described . Cells were untreated or treated with medium containing 10 μM D6 for different times depending on the experiment, then harvested with 0.25% trypsin-EDTA (Sigma-Aldrich, St. Louis, MO, USA) and processed according to the protocol of the specific analysis they have been submitted.
D6 cellular uptake
Melanoma cells were plated in T25 tissue culture flasks (8 × 105 cell/flask) in complete medium; after 24 hours cells were treated or untreated with 10 μM D6 for 1, 2, 4, 6 or 24 hours. At each time, cells were harvested with 0.25% trypsin-EDTA solution (Sigma-Aldrich, St. Louis, MO, USA), washed and resuspended in methanol (1 ml). To achieve D6 extraction, cells in methanol were sonicated for 15 min and the cell lysates were centrifuged at 10,000 rpm for 5 min . The supernatants were transferred and stored at −20°C pending analysis. Immediately prior to analysis, the samples were warmed up to room temperature. After vortexing and centrifugation, 100 μl of the sample were filtered and transferred to a HPLC vial for LC/MS analysis.
LC-grade methanol, acetonitrile, and acetic acid (AA) were purchased from Mallinckrodt J.T. Baker (Deventer, Holland). Water was purified by a Milli-Q Academic System from Millipore (Bedford, MA, USA). Syringe filters (Surfactant Free Cellulose Acetate 0.2 μm 0.13 mm) were purchased from Nalgene Company (Rochester, NY, USA).
Stock solutions of D6 were prepared by dissolving 5 mg of D6 in 10 mL of DMSO (final concentration 500 μg/mL). Stock solutions of D6 were stored at - 20°C in high-density polypropylene cryogenic-vials. Working solution of D6 was prepared daily at the concentration of 100 nM by diluting an aliquot of the stock solutions with the solvent system (Eluent A) and was used to spike samples. Standard curves solutions of D6 at six different concentrations (6.25, 12.50, 25, 50 or 500 nM.) were obtained by adding appropriate concentrations of working solution in samples and solvent system. A 1100 series LC/MSD system (Agilent Technologies, Palo Alto, CA, USA) equipped with a diode-array detector and an autosampler (G1313A) was used for LC separation. Chromatographic separation was achieved using a Polar Plus column (150 mm×2.1 mm, 3 m) (Phenomenex, Torrance, CA, USA) fitted with a 3 μ Polar Plus security guard cartridge (4 mm×2.1 mm) (Phenomenex, Torrance, CA, USA). The column temperature was maintained at 35°C. The mobile phase consisted of Eluent A water with 0.1% HOAc and Eluent B acetonitrile. The separation was performed in a run time of 20 min under gradient conditions with a flow rate of 0.3 mL/min and was followed by clean-up and equilibration stage. The gradient elution ranged from 35% (t = 0 min) to 65% acetonitrile (t = 20 min). The injection volume was 10 μL. Mass spectrometric detection was performed using an Agilent G1946 (MSD 1100) single stage quadrupole instrument equipped with an electrospray atmospheric pressure ionization source. The system was calibrated with the procedures provided by Agilent; the mass spectrometer was optimized with an infusion of 0.5 μg/mL D6 solution at a flow rate of 100 μL/min. The LC/MS system was programmed to divert column flow to waste for 2.5 min after injection, after which time flow was directed into the mass spectrometer that operated in positive ion mode. For quantitative measurement of analytes, selected ion monitoring (SIM) was employed. In the ESI ion source, D6 formed predominantly the ion at m/z 411 ([M+H]+). The following ESI conditions were applied: drying gas (nitrogen) heated at 350°C at a flow rate of 9.5 L/min; nebulizer gas (nitrogen) at a pressure of 42 psi; capillary voltage in positive mode at 3500V; fragmentor voltage at 70V.
Cell cycle progression analysis
LB24 cells were plated in 6-well plates (8 × 105 cells/well), let grown overnight and then treated with either 5 μM or 10 μM D6 for 24 hours. After treatments the cells were harvested with trypsin /EDTA and washed with PBS. Pellets were resuspended in 70% cold ethanol and stored at −20°C until analysis. On the day of analysis, ethanol was removed by centrifugation; pellets were washed with PBS and resuspended in 1 ml of PBS containing 50 μg/mL Propidium Iodide, 100 μg/mL ribonuclease and 100 μg/mL sodium citrate (all from Sigma-Aldrich, St. Louis, MO, USA). Samples were then incubated for 30 min at 4°C in the dark and analyzed by flow cytometry using FACS Canto II (BD Biosciences, San Jose, CA, USA). Data analysis was performed using the ModFit LT 3.0 software (Verity Software House).
Gene expression profile analysis
Total RNA was isolated from LB and BJ cells, untreated or treated with 10 μM D6 for 16 hours, using AllPrep DNA/RNA Mini kit (Qiagen, Inc., Chatsworth, CA) for a total of 12 RNA samples (4 samples in triplicate: LB-C1-3, LB-D61-3, BJ-C1-3, BJ-D61-3). The amount of the total RNA was detected using a NanoDrop 2000 (Thermo Fisher Scientific) and the quality was evaluated by agarose gel electrophoresis. The total RNA samples were normalized and, the mRNAs were amplified and labeled using Illumina® TotalPrep™ RNA Amplification Kit (Ambion®). The system uses the in vitro transcription (IVT) technology, based on the RNA amplification protocol developed by James Eberwine and coworkers . The first reaction of the IVT is a reverse transcription of mRNAs, performed using an oligo(dT) primer tagged with a phage T7 promoter, and convert the mRNA fraction to single-stranded cDNA. Then, a Second-Strand Synthesis reaction converts the single-stranded cDNA in double-stranded cDNA. This product becomes the template for the in vitro transcription performed using a T7 RNA Polymerase and Biotin-NTP mix. The final results of the three reactions are hundreds to thousands of biotinylated, antisense RNA copies of each mRNA per sample. According to the manufacturer’s protocol, labeled cRNAs were quantified, 750 ng of each sample were denaturated at 65°C for 5 min and hybridized on a HumanHT-12 v3 Expression BeadChip (Illumina®) at 58°C overnight. Each well targets 48,803 human probes, representing the whole pool of human expressed genes. After stringency washing, the signal was developed with streptavidin-Cy3, the array slide was dried by centrifugation and scanned using iScan System (Illumina®). Images were processed and signals were quantified and normalized using GenomeStudio software (Illumina®). Probes with detection p-value > 0.05 in more than 9 out of 12 samples were excluded from the statistical analysis.
Statistical analysis was carried out on probes that showed p-values < 0.05 in 9/12 samples, by using the BRB-Array Tools from Biometric Research Branch of National Cancer Institute – NIH (USA). We identified genes that were differentially expressed as an effect of D6 administration using a random-variance t-test. The random-variance t-test is an improvement over the standard separate t-test as it permits sharing information among genes about within-class variation without assuming that all genes have the same variance . Genes were considered statistically significant if their p–value was less than 0.001. A stringent significance threshold was used to limit the number of false positive findings. A per gene FDR was also computed using a univariate permutation test. Briefly, class labels of the samples were randomly permuted N times. For each gene, the permutation p-value is defined as a proportion of permutations for which the p-values of the univariate test are smaller than the p-value computed for the original labeling. Data were further filtered by fold change (FC) considering as differentially expressed probes only those showing 0.5 > FC > 2. The results of the tests are reported in the Additional file 1-A (LB24 melanoma cells) and 2-A (BJ fibroblasts), tabulated along with relevant statistics and hyperlink to gene annotations from the NCBI Entrez gene database. Probes passing the tests were analysed by Ingenuity Pathway Analysis (IPA) software which performs a gene set enrichment analysis and groups genes by biological functional categories and canonical pathways. The p-value reflects the significance of the enrichment of input genes in each functional category or pathway.
Cells were plated in T75 tissue culture flasks in complete medium and grown to semi-confluence, then were treated for 24 hours with medium containing or not 10 μM D6. Cells were harvested using cell-scraper and cold PBS w/o Ca++/Mg++ (Sigma-Aldrich, St. Louis, MO, USA), and then lysed with lysis buffer (50 mM Tris HCl pH 7.5, 5 mM EDTA, 100 mM NaCl, 1 mM Na4P2O7, 1% Triton X100) plus protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). Protein concentration was determined by the QuantiPro BCA Assay Kit (Sigma-Aldrich, St. Louis, MO, USA). Protein lysates (30 μg proteins per lane) were resolved onto 10% or 12% NuPAGE® Novex® Bis-Tris Mini Gels and transferred by iBlot™ Dry Blotting System to iBlot® Gel Transfer Stacks Nitrocellulose, Mini (all from Invitrogen). The membranes were then incubated with primary antibodies over night at 4°C. Primary antibodies used were: mouse monoclonal antibodies against p21, cyclin B1, cdc25, PI3-kinase p85β, c-kit, GAPDH or rabbit polyclonal antibodies against GADD45A, Noxa, p-AKT 1/2/3 (Ser 474), all from Santa Cruz Biotechnology Inc. Detection was achieved by HRP-conjugated anti-mouse (Chemicon, Billerica, MA, USA, 1:10,000) or HRP-conjugated anti-rabbit (Santa Cruz Biotech, 1:1,000,000) antibodies. Immune complexes were visualized with the use of an enhanced chemiluminescence system (ECL Advance™, Amersham International). Protein levels were quantified by ImageJ software  and normalized over (ratio) the GAPDH protein levels used as internal control.
IS and SC were fellows of Sardinia Regional Government (Regione Autonoma della Sardegna). This work has been partially financed by Sardinia Autonomous Region - L.R. 7 August 2007, n.7. We thank Dr. Ana Helena Dias Francesconi for editing advices.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.